Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Ralf Gold; Douglas L. Arnold; Amit Bar‐Or; Michael Hutchinson; Ludwig Kappos; Eva Havrdová; David MacManus; Tarek Yousry; Carlo Pozzilli; Krzysztof Selmaj; Marianne T. Sweetser; Ray Zhang; Minhua Yang; James Potts; Mark Novas; David H. Miller; Nuwan Kurukulasuriya; Robert J. Fox; Theodore Phillips

doi:10.1177/1352458516649037

Abstract

Treatment with DMF was associated with continuously low clinical and magnetic resonance imaging (MRI) disease activity in patients with RRMS. These interim data demonstrate a sustained treatment benefit and an acceptable safety profile with DMF.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gold et al. (2016) studied this question.

synapsesocial.com/papers/69dcc757a5c75be4cfe5429f https://doi.org/10.1177/1352458516649037

View Full Paper

Ask AI

Bookmark

Share

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Abstract

Discussion

Cite This Study

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

Abstract

Discussion

Cite This Study

Keep reading

More from Multiple Sclerosis Journal

Keep reading

More from Multiple Sclerosis Journal